Review
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 21, 2016; 22(31): 6987-7005
Published online Aug 21, 2016. doi: 10.3748/wjg.v22.i31.6987
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
Chiara Caparello, Laura L Meijer, Ingrid Garajova, Alfredo Falcone, Tessa Y Le Large, Niccola Funel, Geert Kazemier, Godefridus J Peters, Enrico Vasile, Elisa Giovannetti
Chiara Caparello, Alfredo Falcone, Niccola Funel, Enrico Vasile, Elisa Giovannetti, University Hospital of Pisa, 56124 Pisa, Italy
Laura L Meijer, Ingrid Garajova, Tessa Y Le Large, Godefridus J Peters, Elisa Giovannetti, Department of Medical Oncology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
Laura L Meijer, Tessa Y Le Large, Geert Kazemier, Department of Surgery, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
Ingrid Garajova, Department of Experimental, Diagnostic and Speciality Medicine, University of Bologna, Sant’Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy
Niccola Funel, Elisa Giovannetti, Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, 56124 Pisa, Italy
Niccola Funel, Elisa Giovannetti, CNR-Nano, Institute of Nanoscience and Nanotechnology, University of Pisa, 56124 Pisa, Italy
Author contributions: Caparello C, Meijer LL, Garajova I and Giovannetti E performed the literature research; Caparello C, Meijer LL and Giovannetti E wrote the paper; Le Large TY, Funel N and Falcone A reviewed the paper; Vasile E, Peters GJ and Kazemier G supervised the project.
Supported by AIRC/Start-Up (to Giovannetti E); Istituto Toscano Tumori ITT-2011 (to Caparello C, Funel N, Vasile E and Giovannetti E), Regione Toscana “Fas Salute” (to Funel N and Giovannetti E), Bennink Foundation (to Meijer LL, Le Large TY, Giovannetti E and Kazemier G), CCA Foundation (to Giovannetti E).
Conflict-of-interest statement: The authors have no conflict of interest to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Elisa Giovannetti, Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, via Paradisa, 2, 56124 Pisa, Italy. elisa.giovannetti@gmail.com
Telephone: +39-05-0996817 Fax: +39-05-0501095
Received: April 29, 2016
Peer-review started: May 2, 2016
First decision: May 30, 2016
Revised: June 9, 2016
Accepted: July 6, 2016
Article in press: July 6, 2016
Published online: August 21, 2016
Core Tip

Core tip: The present manuscript is a review of the state of the art treatments, focusing on biomarkers, target therapies and future perspectives in order to develop personalized treatments.